Clinical Significance of Serum p53 Antibodies in Monitoring Treatment of Syrian Breast Cancer Patients

Abstract

Objective: To determine p53 antibodies in the serum of Syrain breast cancer patients and to assess the prognostic significance of these antibodies in treatment, monitoring and recurrence in those patients. Methods: The study was carried out at the Department of General Surgery at Al-assad university hospital and Al-bairouny oncology education tumor hospital, Damascus, Syria, between April 2008 to February 2011. Serum of 60 patients of breast cancer, 35 patients of benign masses and 35 of healthy controls were analyzed using Enzyme linked immunoadsorbent assay (ELISA). Results: Eight of sixty breast cancer patients were positive for p53 antibodies (13.3%), one patient of 35 benign masses patients was positive for p53 antibodies (2.9%) and p53 Abs weren't detected in control group. When we followed up patients of positive p53Abs after surgery, chemotherapy and radiotherapy, there was a swing in p53 Abs concentration during the study. Conclusion: Our results could support the role of p53 Abs as a prognostic biomarker for patients with breast cancer.